{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Netarsudil+Ophthalmic+Solution&page=2",
    "query": {
      "intervention": "Netarsudil Ophthalmic Solution",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Netarsudil+Ophthalmic+Solution&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T17:08:09.040Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04051463",
      "title": "Rhopressa for Corneal Edema Associated With Fuchs Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fuchs Endothelial Dystrophy"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Price Vision Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2019-08-05",
      "completion_date": "2020-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04051463"
    },
    {
      "nct_id": "NCT02874846",
      "title": "Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil ophthalmic solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-07",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02874846"
    },
    {
      "nct_id": "NCT04057053",
      "title": "Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Fuchs' Endothelial Dystrophy",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-10-02",
      "completion_date": "2020-12-20",
      "has_results": false,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04057053"
    },
    {
      "nct_id": "NCT03233308",
      "title": "Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma or Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-20",
      "completion_date": "2018-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Durham, North Carolina",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233308"
    },
    {
      "nct_id": "NCT06819046",
      "title": "Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan",
          "type": "DRUG"
        },
        {
          "name": "Systane Ultra",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Colorado Ophthalmology Associates PC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-02-14",
      "completion_date": "2025-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819046"
    },
    {
      "nct_id": "NCT02246764",
      "title": "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "19 Years to 99 Years"
      },
      "enrollment_count": 93,
      "start_date": "2014-09",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246764"
    },
    {
      "nct_id": "NCT04234932",
      "title": "Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of the Incarnate Word",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-06",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-14",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234932"
    },
    {
      "nct_id": "NCT06394973",
      "title": "Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "T4090 0.2%",
          "type": "DRUG"
        },
        {
          "name": "T4090 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Rhopressa®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2024-08-05",
      "completion_date": "2024-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 24,
      "location_summary": "Glendale, Arizona • Glendale, California • Inglewood, California + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06394973"
    },
    {
      "nct_id": "NCT04752020",
      "title": "Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Fuchs' Endothelial Dystrophy"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-03-28",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752020"
    },
    {
      "nct_id": "NCT01997879",
      "title": "Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution, 0.02%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2013-11",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-09-25T17:08:09.040Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997879"
    }
  ]
}